News Kronos Bio, Inc.

Equities

KRON

US50107A1043

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.96 ^USD	+1.05%		-7.69%	-23.20%

Mar. 21	Earnings Flash (KRON) KRONOS BIO Reports Q4 Revenue $2.3M	MT
Mar. 21	Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	Apr. 24	GL
Earnings Flash (KRON) KRONOS BIO Reports Q4 Revenue $2.3M	Mar. 21	MT
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results	Mar. 21	GL
Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Kronos Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway	Mar. 07	GL
Kronos Bio, Inc. Announces to Assess KB-0742 At Planned New Dose Schedule in Ongoing Phase 1/2 Study	Mar. 07	CI
Kronos Bio Plans to Reduction in Force	Mar. 07	CI
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting	Mar. 05	GL
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference	Feb. 27	GL
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference	Feb. 27	AQ
Kronos Bio Announces Management Shakeup, 3 Top Managers to Step Down in February	Jan. 25	MT
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement	Jan. 25	GL
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement	Jan. 25	AQ
Kronos Bio, Inc. Announces Executive Changes	Jan. 25	CI
Investors got more clues that rate cuts are imminent	Dec. 19
Piper Sandler Trims Price Target on Kronos Bio to $6 From $7, Keeps Overweight Rating	Dec. 19	MT
HC Wainwright Adjusts Price Target on Kronos Bio to $2.50 From $9, Keeps Buy Rating	Dec. 19	MT
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate	Dec. 18	GL
Kronos Bio, Inc. Announces Pipeline Update and p300 KAT Inhibitor Development Candidate	Dec. 18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kronos Bio, Inc.

Equities

KRON

US50107A1043

Summary

Filters